Overview

Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Ampicillin
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Sulbactam
Sultamicillin
Tazobactam